Resverlogix Corp. (RVX.TO)
| Previous Close | 0.2550 |
| Open | 0.3000 |
| Bid | 0.2350 x 0 |
| Ask | 0.2550 x 0 |
| Day's Range | 0.2300 - 0.3000 |
| 52 Week Range | 0.2200 - 0.8300 |
| Volume | |
| Avg. Volume | 68,153 |
| Market Cap | 60.655M |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | 17.86 |
| EPS (TTM) | 0.0140 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows: Votes ForVotes WithheldPercent ForPercent WithheldDonald J. McCaffrey125,007,1427,
- Baystreet
Stocks in play: Resverlogix Corp.
Today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D chromatin ...
- GlobeNewswire
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators” in the journal Biomedicine & Pharmacotherapy. The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors in comparison with non-selective B
